PRINCETON, N.J., Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. Sequire Investor Summit, held January 21 to 23 at Condado Vanderbilt, Puerto Rico. For more information about the Sequire Investor Summit, please re ...

Study Supported by $2.6 Million FDA Orphan Products Development GrantPRINCETON, N.J., Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early- ...

FLASH2 Study opens patient enrollmentPRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study (F ...

Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™PRINCETON, N.J., Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol HPN-CTCL-04) comparing HyBryte™ (synthetic hypericin) to Valchlor® (mechlorethamine) has ...

Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicen ...

Study DUS-AUBD-01 opens patient enrollmentPRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease."We are pleased to have received FDA cl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File No. 001-14778 SOLIGENIX, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- ...

Core Insights - Soligenix, Inc. is focused on developing treatments for rare diseases with unmet medical needs and has announced recent accomplishments and financial results for Q3 2024 [1] Recent Accomplishments - The Hong Kong Patent Office granted a patent for a novel proprietary process of producing highly purified synthetic hypericin on October 22, 2024 [3] - Lead investigators presented findings on HyBryte™ for CTCL treatment at a European cancer research organization on October 7, 2024 [3] - A partnership with Sterling Pharma Solutions was established to optimize production technology for synthetic hypericin on October 3, 2024 [3] - The European Patent Office granted a similar patent for synthetic hypericin production on September 3, 2024 [3] Clinical Activities and Milestones - The company plans to initiate a Phase 3 placebo-controlled study for HyBryte™ in early-stage CTCL by year-end 2024 [2] - A Phase 2 study for SGX945 in Behçet's disease is set to begin shortly, with top-line results expected in the first half of 2025 [2] - Data from the ongoing Phase 2 study of SGX302 in mild-to-moderate psoriasis is anticipated in the first half of 2025 [2] Financial Results - Soligenix reported no revenue for Q3 2024, compared to $0.1 million in Q3 2023, with revenues primarily from government contracts and grants [4] - The net loss for Q3 2024 was $1.7 million, or ($0.78) per share, consistent with the loss in Q3 2023, which was ($2.56) per share [5] - Research and development expenses increased to $1.0 million in Q3 2024 from $0.8 million in Q3 2023, attributed to costs for new clinical studies [6] - General and administrative expenses decreased to $0.9 million in Q3 2024 from $1.0 million in Q3 2023, mainly due to lower legal and professional fees [7] - As of September 30, 2024, the company's cash position was approximately $9.8 million [7]

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institut ...

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of PsoriasisPRINCETON, N.J., Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". ...